60
Participants
Start Date
March 25, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
January 31, 2027
liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
The intervention in this study is a tailored antifungal regimen combining liposomal amphotericin B (L-AmB) (3-5 mg/kg/day IV) with posaconazole or isavuconazole (300 mg/200 mg daily, oral or IV), designed to optimize efficacy and safety in immunocompromised adults with blood cancers and mucormycosis. Dosing and duration are personalized based on clinical response, immune recovery, and organ function, with a focus on transitioning to oral therapy to reduce hospitalization. The study emphasizes rigorous safety monitoring, prohibited unauthorized antifungal co-medications, and explores prognostic factors to advance treatment strategies for this high-risk population.
NOT_YET_RECRUITING
Tianjin First Central Hospital, Tianjin
NOT_YET_RECRUITING
The Second Hospital of Dalian Medical University, Dalian
NOT_YET_RECRUITING
The First Affiliated Hospital of Harbin Medical University, Harbin
NOT_YET_RECRUITING
Shengjing Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
The First Affiliated Hospital of China Medical University, Shenyang
RECRUITING
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
NOT_YET_RECRUITING
Second Hospital of Tianjin Medical University, Tianjin
NOT_YET_RECRUITING
Tianjin Haihe Hospital, Tianjin
NOT_YET_RECRUITING
Tianjin Union Medical Center of Nankai University, Tianjin
Institute of Hematology & Blood Diseases Hospital, China
OTHER